LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

96.04 -1.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

95.88

Max

98.45

Põhinäitajad
By Trading Economics
Sissetulek	64M 118M
Müük	-29M 377M
P/E Sektori keskmine	23.181 49.888
Aktsiakasum	1.46
Kasumimarginaal	31.383
Töötajad	1,193
EBITDA	-17M 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+6.77% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	609M 6.3B
Eelmine avamishind	97.25
Eelmine sulgemishind	96.04

Uudiste sentiment

By Acuity

13%

87%

20 / 344 Pingereas Healthcare

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2026, 20:30 UTC

Tulu

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. juuni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. juuni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. juuni 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. juuni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. juuni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. juuni 2026, 21:00 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. juuni 2026, 20:46 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:38 UTC

Tulu

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. juuni 2026, 20:21 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:12 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Product Rev $594M

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Loss $177M >PANW

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

6.77% tõus

12 kuu keskmine prognoos

Keskmine 103.71 USD 6.77%

Kõrge 115 USD

Madal 90 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

20 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.